We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Osteoporosis often occurs in the elderly, and is a systemic bone metabolism disease characterized by low bone mass and destruction of the bone microstructure, leading to increased bone fragility and tendency of fracture. It is well known that endogenous parathyroid hormone (PTH), an 84-residue polypeptide synthesized, stored, and secreted by parathyroid epithelial cells, plays an essential role in regulating bone metabolism. PTH1–34 is a 34 amino acid residue fragment at the N-terminus of PTH, and has been approved by U.S. Food and Drug Administration for the treatment of osteoporosis, yet has a short half-life and requires frequent injection during its administration.
We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy